Pancreatic cancer: Progress in cancer therapy

Pierantoni, Chiara; Pagliacci, A.; Scartozzi, Mario; Berardi, Rossana; Bianconi, Maristella; Cascinu, Stefano

doi:10.1016/j.critrevonc.2008.01.009

Cited by 31 publications

(24 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Treatment of patients with locally advanced and metastatic disease therefore is generally for palliation. 11 After adjusting for other clinical and demographic variables African Americans were less often given chemotherapy and Hispanics less often received radiation than non-Hispanic whites.…”

Section: Discussionmentioning

confidence: 99%

Racial/Ethnic Patterns of Care for Pancreatic Cancer

Shavers

Harlan

Jackson

et al. 2009

Journal of Palliative Medicine

View full text Add to dashboard Cite

Introduction: The small proportion of cancers diagnosed at the local disease stage, resectable at the time diagnosis, and responsive to chemotherapy contribute to poor survival making pancreatic cancer the fourth leading cause of cancer death among Americans. This emphasizes the importance of receiving appropriate palliative care. Racial=ethnic cancer treatment disparities have been observed for many cancer sites. We examine patterns of care in a population-based sample of African American, Hispanic and non-Hispanic white patients diagnosed with pancreatic cancer. Methods: Eligible cases were age 20 or older and newly diagnosed in 1998 with primary adenocarcinoma of the pancreas reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program and selected for the NCI Patterns of Care=Quality of Care (POC=QOC) project (n ¼ 697). Results: Chemotherapy, the most frequently received treatment was less frequently received by African American patients (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.37-0.95) and radiation less frequently received by Hispanic compared to non-Hispanic white white patients (OR 0.50, 95% CI, 0.27-0.95) after adjustment for age, stage, size of tumor, and insurance status in a multivariate regression model. Cancer-directed surgery of the primary site was received by 14.1% of patients, which did not significantly differ by race= ethnicity. Uninsured patients less often were recommended for or received surgery (OR 0.09, 95% CI 0.01-0.62) and (OR 0.07, 95% CI, 0.01-0.49), respectively. Conclusion: Differences in primary tumor size, stage and insurance status contributed to racial=ethnic differences in the receipt of cancer-directed surgery but did not explain differences in the receipt of chemotherapy for African American or radiation for Hispanic patients. More population-based research is needed to examine race=ethnicity, insurance status and receipt of treatment and palliative care for pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Racial/Ethnic Patterns of Care for Pancreatic Cancer

Shavers

Harlan

Jackson

et al. 2009

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

“…Mean survival of patients with untreated pancreatic cancer is less than six months, and five-year survival is less than 5% [1,3]. Pancreaticoduodenectomy, as described by Whipple and colleagues, is the standard of care for patients with localized pancreatic cancer [4].…”

Section: Introductionmentioning

confidence: 98%

“…Pancreatic cancer is the fourth leading cause of cancerrelated death in the United States, with approximately 37,000 new cases and 34,000 deaths related to this cancer every year [1,2]. Mean survival of patients with untreated pancreatic cancer is less than six months, and five-year survival is less than 5% [1,3].…”

Section: Introductionmentioning

confidence: 99%

Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Use of CX3CR1 as a possible therapeutic candidate is discussed in detail elsewhere [165] . Pancreatic cancer is one of the most aggressive and intractable malignancies amongst all cancers [166] . Therefore, finding molecular markers to facilitate accurate diagnosis at early stages of disease is an urgent need.…”

Section: Pancreasmentioning

confidence: 99%

Chemokines, chemokine receptors and the gastrointestinal system

Miyazaki¹,

Takabe²,

Yeudall³

2013

WJG

View full text Add to dashboard Cite

Core tip: The chemokine network makes an attractive target for therapeutic intervention in many tumor types, including those of the gastrointestinal tract. However, we need to define more selective and specific targets, to minimize systemic side effects during treatment. INTRODUCTION Cancer development and progression in the gastrointestinal tractCancer is a disease in which normal cells acquire genetic and epigenetic abnormalities [1,2] , leading to disorientation of conventional processes for the maintenance of normal cell physiology. These aberrant genetic and epigenetic modifications to the normal cell induce abnormal cell motility, proliferation, and survival, eventually enabling these cells to invade into adjacent tissues and even to migrate to regional or distant organs where they may grow continuously as metastatic lesions [3] . For many cancer patients, metastasis is generally the major cause of disease-related death [4,5] . Therefore, it is indispensable to elucidate the basic molecular mechanisms of tumor development to identify effective therapeutic targets, which can possibly reduce the side-effects of treatment, and define useful molecular markers for early detection and prediction of disease course. Especially, the newly emerged concept of personalized medicine may require in-depth assessment of potential therapeutic molecular target(s) in each individual case through analysis of sig- REVIEW Chemokines, chemokine receptors and the gastrointestinal system AbstractThe biological properties of tumor cells are known to be regulated by a multitude of cytokines and growth factors, which include epidermal growth factor receptor agonists and members of the transforming growth factor β family. Furthermore, the recent explosion of research in the field of chemokine function as mediators of tumor progression has led to the possibility that these small, immunomodulatory proteins also play key roles in carcinogenesis and may, therefore, be potential targets for novel therapeutic approaches. In this review, we will summarize recently reported findings in chemokine biology with a focus on the gastrointestinal tract.

show abstract

Pancreatic cancer: Progress in cancer therapy

Cited by 31 publications

References 69 publications

Racial/Ethnic Patterns of Care for Pancreatic Cancer

Racial/Ethnic Patterns of Care for Pancreatic Cancer

Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases

Chemokines, chemokine receptors and the gastrointestinal system

Contact Info

Product

Resources

About